Clinical Trial Update: Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AGB101 for reducing hippocampal overactivity in older adults is currently recruiting. Sponsor is Johns Hopkins University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia

Drugs mentioned

• AGB101

Snippet

Sponsor: Johns Hopkins University | Conditions: Hippocampal Overactivity, Dementia | Phase 2 | Status: RECRUITING